Polypharmacy but not Potential Inappropriate Prescription Was Associated with Frailty in Older Adults from a Middle-Income Country Outpatient Clinic

被引：7

作者：

Aprahamian I. ^{[1
,2
]}

Biella M.M. ^{[2
]}

Vano Aricó De Almeida G. ^{[1
]}

Pegoraro F. ^{[1
]}

Alves Pedrini A.V. ^{[1
]}

Cestari B. ^{[1
]}

Bignotto L.H. ^{[1
]}

Alvarez Ribeiro De Melo B. ^{[1
]}

Martinelli J.E. ^{[1
]}

机构：

[1] Investigation on Multimorbidity and Mental Health in Aging (IMMA) Lab, Department of Internal Medicine, Faculty of Medicine of Jundiaí, Rua Francisco Telles, 250, State of São Paulo, Vila Arens, Jundiaí

[2] Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, University of São Paulo, São Paulo

来源：

The Journal of Frailty & Aging | 2018年 / 7卷 / 2期

关键词：

elderly; Frailty; polypharmacy;

D O I：

10.14283/jfa.2018.5

中图分类号：

学科分类号：

摘要：

Objectives: the aims of the present study were: (1) investigate the prevalence and association of polypharmacy and pre-frailty or frailty in a middle-income country sample of older adults; and (2) evaluate the prevalence of potential inappropriate prescription (PIP) and its association with pre-frailty or frailty. Design: Cross-sectional observational study. Setting: Outpatient center at a university-based hospital in the state of São Paulo, Brazil. Participants: 629 older adults from both sexes evaluated between June 2014 and July 2016. Measurements: Frailty was identified through the FRAIL scale. All medications received were analyzed by research staff. Presence of PIP was evaluated according to the 2015 updated Beers list. Binary logistic regression tested the association between 4 definitions of polypharmacy (≥ 3, 4, 5, and 6 drugs), and presence of PIP, and the dependent variable pre-frailty and frailty. Results: 15.7% of participants were frail. Polypharmacy was present in 219 (34.8%), and PIP was observed in 184 (29.3%) older adults. All definitions of polypharmacy were significantly associated with frailty (OR between 2.05 to 2.34, p < 0.001). Polypharmacy with 4 or 5 or more drugs were associated with pre-frailty (OR 1.53 and 1.47, respectively). PIP was not associated with frailty (OR 1.47, p = 0.149). Conclusions: Several definitions of polypharmacy were associated with frailty, but only two were associated with pre-frailty. The presence of PIP was not associated with pre-frailty or frailty. © 2018, Serdi and Springer Nature Switzerland AG.

引用

页码：108 / 112

页数：4

共 28 条

[1]

Clegg A., Young J., Iliffe S., Et al., Frailty in elderly people, Lancet, 2, pp. 752-762, (2013)

[2]

Morley J.E., Vellas B., van Kan G.A., Et al., Frailty Consensus: A Call to Action, J Am Med Dir Assoc, 14, pp. 392-397, (2013)

[3]

Collard R.M., Boter H., Schoevers R.A., Oude Voshaar R.C., Prevalence of frailty in community-dwelling older persons: a systematic review, J Am Geriatr Soc, 60, pp. 1487-1492, (2012)

[4]

Da Mata F.A., Pereira P.P., Andrade K.R., Figueiredo A.C., Silva M.T., Pereira M.G., Prevalence of Frailty in Latin America and the Caribbean: A Systematic Review and Meta-Analysis, PLoS One, 11, 8, (2016)

[5]

Espinoza S.E., Hazuda H.P., Frailty in older Mexican-American and European American adults: Is there an ethnic disparity, J Am Geriatr Soc, 56, pp. 1744-1749, (2008)

[6]

Wise J., Polypharmacy: A necessary evil, BMJ, 347, (2013)

[7]

Saum K.U., Schottker B., Meid A.D., Et al., Is polypharmacy associated with frailty in older people? Results from the ESTHER Cohort Study, J Am Geriatr Soc, 65, 2, pp. e27-e32, (2017)

[8]

Hartikainen S., Lonnroos E., Louhivuori K., Medication as a risk factor for falls: critical systematic review, J Gerontol A Biol Sci Med Sci, 62, 10, pp. 1172-1181, (2007)

[9]

Herr M., Robine J.M., Pinot J., Arvieu J.J., Ankri J., Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people, Pharmacoepidemiol Drug Saf, 24, 6, pp. 637-646, (2015)

[10]

Jyrkka J., Enlund H., Lavikainen P., Sulkava R., Hartikainen S., Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population, Pharmacoepidemiol Drug Saf, 20, 5, pp. 514-522, (2011)

← 1 2 3 →